Translational Imaging Center To Open in Spring 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Translational Imaging Center To Open in Spring 2014



MPI Research, inviCRO, and 3D Imaging announced the name of a new advanced imaging center being built at the MPI Research headquarters in Mattawan, Mich. A joint partnership by the three organizations, the Translational Imaging Center, is the first resource for the drug development community to combine molecular imaging, autoradiography, and animal modeling with an onsite cyclotron, vivarium, and advanced image analytics, the companies report.

When completed in Spring 2014, the Center will have the have the ability to translate preclinical data to clinical data, giving drug developers access to imaging, radiochemistry, and informatics solutions to enable faster, better informeddecisions regarding a drug candidate’s potential, according to a press release.

MPI Research, inviCRO, and 3D Imaging’spartnership on the development and operation of the Translational Imaging Center aims to address increasing demand from pharmaceutical and other Iife- science companies for comprehensive imaging services in one location.

Sponsors will be able to enhance their decision-making process based on evaluating three primary criteria: exposure at the target site, binding to the pharmacological target, and expression of the intended pharmacology. When applied to early and mid-stage development, these imaging solutions answer key questions about drug candidates with just a handful ofstudies. For late-stage developers, molecular imaging in concert with otherdiagnostic processes in nonhuman primate models can define the best dosages for future clinical trials, the companies report.

The 10,000-sq-ft, two-story Translational Imaging Center groundbreaking was held in September 2013 and is scheduled to open in the Spring 2014.

Source: MPI Research

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here